Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed By Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind phase 3 Study (HOVON 181 AML / AMLSG 37-25)
Year: 2026
Type: article
Authors: Marc Raaijmakers, Hartmut Döhner, Dimitri Breems, John C. Byrd, Konstanze Döhner, Jordi Esteve, Bjørn Tore Gjertsen, Patrycja Gradowska, Gerwin Huls, Ain Kaare, Hee-Je Kim, Hitoshi Kiyoi, Mika Kontro, Janusz Krawczyk, Vladimir Lazarevic, Andrea Lenartova, Alice Mims, Jeannine M. Refos, Christoph Röllig, Anika Schrade, Karolina Sikorska, Alexandre Theocharides, Peter Valk, Adriano Venditti, Jianxiang Wang, Andrew H. Wei, Agnieszka Wierzbowska, Andrius Žučenka, Lucille Ferrante, Christina Guttke, Angélique Langlois, Christina Loefgren, Kathryn Packman, Prathap Nagaraja Shastri, Natasha Schuier, Meena Thayu, Danielle Trancucci, Bob Lowenberg, Lars Bullinger
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7127434395
FWCI:
Cites:
Cited by:
Related to: